Advanced

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

Kanis, JA; Borgstrom, F; Johnell, Olof LU ; Oden, A; Sykes, D and Jonsson, B (2005) In Osteoporosis International 16(1). p.15-25
Abstract
Raloxifene treatment has been shown to reduce the risk of vertebral fractures and breast cancer in postmenopausal women. The long-term economic implications of treatment with raloxifene have not yet been investigated. The aim of this study was to assess the cost-effectiveness of treating postmenopausal women in the UK with raloxifene. A previously developed computer simulation model was used to estimate the cost-effectiveness of osteoporotic treatments with extra skeletal benefits. The model was populated with epidemiological data and cost data relevant for a UK female population. Data on the effect of treatment were taken from the Multiple Outcomes of Raloxifene (MORE) study., which recruited women with low bone mineral density or with a... (More)
Raloxifene treatment has been shown to reduce the risk of vertebral fractures and breast cancer in postmenopausal women. The long-term economic implications of treatment with raloxifene have not yet been investigated. The aim of this study was to assess the cost-effectiveness of treating postmenopausal women in the UK with raloxifene. A previously developed computer simulation model was used to estimate the cost-effectiveness of osteoporotic treatments with extra skeletal benefits. The model was populated with epidemiological data and cost data relevant for a UK female population. Data on the effect of treatment were taken from the Multiple Outcomes of Raloxifene (MORE) study., which recruited women with low bone mineral density or with a prior vertebral fracture. Cost-effectiveness was estimated using Quality Adjusted Life Years (QALYs) and life years gained as primary outcome measures. The cost per QALY gained of treating post menopausal women without prior vertebral fractures was pound18,000, pound23,000, pound18,000 and pound21,000 at 50. 60, 70 and SO years of age. Corresponding estimates for women with prior vertebral fractures were pound10,000, pound24,000, pound18,000 and pound20,000. In relation to threshold values that are recommended in the UK. the analysis suggests that raloxifene is cost-effective in the treatment of postmenopausal women at an increased risk of vertebral fractures. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
vertebral fracture, raloxifene, breast cancer, cost-effectiveness
in
Osteoporosis International
volume
16
issue
1
pages
15 - 25
publisher
Springer
external identifiers
  • wos:000226284900003
  • pmid:15672210
  • scopus:13244277629
ISSN
1433-2965
DOI
10.1007/s00198-004-1688-0
language
English
LU publication?
yes
id
545df805-9ca6-42ed-a2cb-f22070771f3c (old id 897683)
date added to LUP
2008-01-16 12:31:24
date last changed
2017-08-27 05:09:06
@article{545df805-9ca6-42ed-a2cb-f22070771f3c,
  abstract     = {Raloxifene treatment has been shown to reduce the risk of vertebral fractures and breast cancer in postmenopausal women. The long-term economic implications of treatment with raloxifene have not yet been investigated. The aim of this study was to assess the cost-effectiveness of treating postmenopausal women in the UK with raloxifene. A previously developed computer simulation model was used to estimate the cost-effectiveness of osteoporotic treatments with extra skeletal benefits. The model was populated with epidemiological data and cost data relevant for a UK female population. Data on the effect of treatment were taken from the Multiple Outcomes of Raloxifene (MORE) study., which recruited women with low bone mineral density or with a prior vertebral fracture. Cost-effectiveness was estimated using Quality Adjusted Life Years (QALYs) and life years gained as primary outcome measures. The cost per QALY gained of treating post menopausal women without prior vertebral fractures was pound18,000, pound23,000, pound18,000 and pound21,000 at 50. 60, 70 and SO years of age. Corresponding estimates for women with prior vertebral fractures were pound10,000, pound24,000, pound18,000 and pound20,000. In relation to threshold values that are recommended in the UK. the analysis suggests that raloxifene is cost-effective in the treatment of postmenopausal women at an increased risk of vertebral fractures.},
  author       = {Kanis, JA and Borgstrom, F and Johnell, Olof and Oden, A and Sykes, D and Jonsson, B},
  issn         = {1433-2965},
  keyword      = {vertebral fracture,raloxifene,breast cancer,cost-effectiveness},
  language     = {eng},
  number       = {1},
  pages        = {15--25},
  publisher    = {Springer},
  series       = {Osteoporosis International},
  title        = {Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study},
  url          = {http://dx.doi.org/10.1007/s00198-004-1688-0},
  volume       = {16},
  year         = {2005},
}